Swing Trading Room – The Details Are Here

How to Subscribe: First, go here - http://drkkd.com/whats-on-offer/ - and select the swing trading option on the top right hand corner. Trial is for 2 months, $40; thereafter, if you wish to continue, it is $1199/yearly. If you subscribe now, but wish to cancel before the annual payment kicks in [...]

By |January 27th, 2017|News|0 Comments

$DMTX reports Q3 results

Dimension Therapeutics $DMTX reported Q3 EPS of -$0.58, missing the guidance by $0.03. Revenue was $2.76 million, a growth of 34%, Y-o-Y, and beating the estimate by $0.6 million.

By |November 10th, 2016|News|0 Comments

$BMY signs global licensing agreement with Nitto Denko

Bristol-Myers Squibb $BMY signed a global licensing agreement with Japanese firm Nitto Denko $NDEKF for the development and commercialization of Nitto�s siRNA molecules targeting heat shock protein 47 (HSP47) formulations containing vitamin A. The agreement includes Nitto�s lead product candidate, Phase 1b-stage ND-L02-s0201, for the treatment of advanced liver fibrosis [...]

By |November 10th, 2016|News|0 Comments

$ANTH CHABLIS-SCI fails

Anthera Pharmaceuticals� $ANTH fell sharply amid heavy trading volume in response to its announcement that CHABLIS-SC1, evaluating blisibimod for the treatment of patients with active systemic lupus erythematosus (SLE) failed to achieve its primary endpoint.

By |November 10th, 2016|News|0 Comments

$TENX reports Q3 results

Tenax Therapeutics $TENX posted Q3 EPS of -$0.15, beating the guidance by $0.02.

By |November 10th, 2016|News|0 Comments

$AZN reports Q3 results

AstraZeneca $AZN reported Q3 EPS of $1.32, beating the guidance by $0.58. Revenue was $5.7 billion, a drop of 4.2$, Y-o-Y, and missing the estimate by $250 million.

By |November 10th, 2016|News|0 Comments

$PFE considering sale or spin-off of consumer health unit

Pfizer $PFE is considering a potential sale or spinoff of its consumer health unit that could value the business as much as $14 billion, according to Reuters� report. Divesting this division, which includes Advil and Chapstick, would be one the company biggest ever corporate moves since cancelling a $160 billion [...]

By |November 10th, 2016|News|0 Comments

$AST First Subject Receives Highest Dose

The first subject received the highest dose of 20M cells in Asterias Biotherapeutics� $AST Phase 1/2a Clinical Trial, labeled as SCiSTAR, evaluating AST-OPC1 (oligodendrocyte progenitor cells) in patients with complete cervical spinal cord injury. The purpose of the dose escalation is to build a thorough safety profile before advancing to [...]

By |November 8th, 2016|News|0 Comments

$GALT Reports Q3 Results

Galectin Therapeutics $GALT reported Q3 EPS of -$0.19, beating the guidance by $0.03. Cash and cash equivalents at the end of the quarter were $16.06 million.

By |November 8th, 2016|News|0 Comments

$RMTI Drops After Earnings

Rockwell Medical $RMTI fell sharply after it reported an 11.1% drop in total sales of 12.8 million for the fiscal third quarter. Net income was ($4.6) million, a drop of 89.9%, Y-o-Y. EPS was $(0.09). Cash flows from operations for the nine months period were at $13 million, an increase [...]

By |November 8th, 2016|News|0 Comments

$INNL’s INL-002 fails to beat COGENZIA

Innocoll Holdings $INNL came under a heavy selling pressure in response to its announcement that its pipeline candidate INL-002, branded as COGENZIA (gentamicin collagen topical matrix), failed to beat standard-of-care (SOC)�treatment (systemic antibiotics and wound therapy) in two Phase 3 clinical trials in patients with moderate-to-severe diabetic foot ulcers.Both clinical [...]

By |November 4th, 2016|News|0 Comments

$GNVC reports Q3 results

GenVec $GNVC reported Q3 EPS of -$0.05, beating the guidance by $0.03. Revenue was $0.17 million, a drop of 10.5% Y-o-Y but beating the estimate by $0.1 million.

By |November 4th, 2016|News|0 Comments

$OMER obtains funding

Omeros $OMER concluded an $80 million term loan under its $125 million senior secured credit facility with affiliates of investment firm CRG LP. Funds received under the credit facility will be mainly utilized ($76 million) to repay indebtedness under its previous credit facility and the remaining will be utilized to [...]

By |November 4th, 2016|News|0 Comments

$EGLT Reports Q3 results

Egalet $EGLT reported Q3 EPS of -$1.10, missing the guidance by $0.20. Revenue was $4.71 million, a growth of 178.7%, Y-o-Y but beating the estimate by $0.12 million.

By |November 4th, 2016|News|0 Comments

$REGN reports Q3 results

Regeneron Pharmaceuticals $REGN reported Q3 EPS of $3.13, beating the guidance by $0.42. Revenue was $1.22 billion, a growth of 7%, Y-o-Y, but missing the revenue by $70 million.

By |November 4th, 2016|News|0 Comments

$AGN, $VTAE Deal in Jeopardy

Allergan�s $AGN planned $640 million acquisition of Vitae Pharmaceuticals, which was likely to close this quarter, apparently has hit a roadblock after analysts reported that one of its two main pipeline candidates VTP-38543, failed to show a treatment benefit in a Phase 2 clinical trial in atopic dermatitis. It now [...]

By |November 3rd, 2016|News|0 Comments

$ACAD Commences ENHANCE-1

ACADIA Pharmaceuticals $ACAD started a Phase 3 study, dubbed as ENHANCE-1, evaluating NUPLAZID (pimavanserin) for adjunctive treatment of schizophrenia in patients who have failed to respond to antipsychotic therapy, a symptom that affects roughly 30% of schizophrenia victims.

By |November 3rd, 2016|News|0 Comments

$VICL Misses Q3 Revenue Guidance

Vical $VICL reported Q3 revenue of $2.64 million, a plunge of 47.4%, Y-o-Y and missing the guidance by $1.96 million. EPS was -$0.24 beating the forecast by $0.01. The company�s net cash used for the nine months period of 2016 was $6.8 million, which was in-line with company�s guidance for [...]

By |November 3rd, 2016|News|0 Comments

$AMRN Posts Q3 Earnings

Amarin $AMRN posted Q3 EPS of -$0.08, beating the guidance by $0.02. Revenue for the quarter was $32.77, a growth of 52.4% Y-o-Y, and beating the guidance by $0.7 million.

By |November 3rd, 2016|News|0 Comments

$RDUS Reports Q3 Results

Radius Health $RDUS posted a net loss of $46.2 million or -$1.07 a share, missing the guidance by $0.04. The company reported a net loss of $28.3 million or -$0.68 a share in the corresponding period of last year. The rise in net loss for the three months ended September [...]

By |November 3rd, 2016|News|0 Comments
s2Member®